BioCardia regains Nasdaq $1 minimum bid compliance
BioCardia has regained compliance with Nasdaq’s $1.00 minimum bid price rule, closing a prior listing deficiency but acknowledging future compliance is not assured.
Rhea-AI Filing Summary
BioCardia, Inc. (BCDA) reports that Nasdaq has determined the company has regained compliance with the Nasdaq Capital Market’s $1.00 minimum bid price requirement. The Nasdaq staff confirmed that BioCardia’s common stock closed at or above $1.00 per share for at least 10 consecutive business days, and the deficiency matter is now closed. The stock continues to trade on the Nasdaq Capital Market under the symbol BCDA. The company notes there is no assurance it will be able to maintain compliance with this requirement in the future.
Positive
- Regains Nasdaq listing compliance after meeting the $1.00 minimum bid price for at least 10 consecutive business days, closing the prior deficiency and keeping BCDA on the Nasdaq Capital Market.
Negative
- Ongoing listing risk remains as the company cautions there is no assurance it will maintain compliance with Nasdaq’s Minimum Bid Price Requirement in the future.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Nasdaq minimum bid price: $1.00 per share
Non-compliance period: 30 consecutive business days
Compliance measurement period: 10 consecutive business days
+2 more
5 metrics
Nasdaq minimum bid price
$1.00 per share
Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market
Non-compliance period
30 consecutive business days
Period when closing bid price was below $1.00 prior to the August 19, 2026 notice
Compliance measurement period
10 consecutive business days
Days BCDA’s closing bid price was at or above $1.00 before Nasdaq deemed compliance regained
Initial Nasdaq notice date
August 19, 2026
Date Nasdaq informed BioCardia of non-compliance with the Minimum Bid Price Requirement
Regained compliance notice date
September 21, 2026
Date Nasdaq notified BioCardia that it had regained compliance
Key Terms
Minimum Bid Price Requirement, Nasdaq Capital Market, forward-looking statements
3 terms
Minimum Bid Price Requirement regulatory
"the minimum price of the Company’s common stock had been below the $1.00 per share minimum requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Capital Market regulatory
"continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
forward-looking statements regulatory
"contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq compliance update did BioCardia (BCDA) announce?
BioCardia announced that Nasdaq determined the company has regained compliance with the $1.00 per share Minimum Bid Price Requirement for continued listing on the Nasdaq Capital Market after its stock closed at or above $1.00 for at least 10 consecutive business days.
Why was BioCardia (BCDA) previously out of compliance with Nasdaq rules?
On August 19, 2026, Nasdaq notified BioCardia that for the last 30 consecutive business days, the closing bid price of its common stock had been below the $1.00 per share minimum required under Nasdaq Listing Rule 5550(a)(2).
When did BioCardia regain compliance with Nasdaq’s minimum bid price requirement?
On September 21, 2026, Nasdaq staff notified BioCardia in writing that its common stock had closed at or above $1.00 per share for at least 10 consecutive business days, and that it had regained compliance with the Minimum Bid Price Requirement.
Is future Nasdaq compliance guaranteed for BioCardia (BCDA)?
No. BioCardia notes that while it has regained compliance with the Minimum Bid Price Requirement, there can be no assurance the company will be able to maintain compliance with this requirement in the future.
AI-generated analysis. How Rhea-AI works. Not financial advice.
